This is still an ongoing challenge for researchers, but based on what is known regarding tumour response to immune checkpoint inhibitors by other cancers, tumour mutation burden (i.e., lung cancer) and microsatellite instability (i.e., colon cancer) seem to be the most useful markers besides PD-1/PD-L1 score [106,107]. The gene discussed is PDCD1; the disease is neoplasm.